Bioextrax (BIOEX) investor relations material

Business model and scale-up

• Global patented technologies, Lund headquarters and R&D, Nasdaq First North listing, and a licensing model across PHA plastics and feather-derived feed ingredients.

• Demonstration facility has 2 x 1,000 L fermenters at TRL 7; supports large-scale samples, process optimization, and validation toward industrial scale.

• The facility is a core part of the capital-light licensing model.

PHA business

• PHA demand is supported by legislation including EU microplastics legislation and PPWR; PHA is biodegradable in marine, soil, and compost environments.

• PHBV targets a market with established producers; R&D focuses on lowering production costs and diversifying raw material sources.

• PHO has elastic, film-forming properties and no existing large-scale producer; development targets applications including chewing gum, personal care, and adhesives.

• PHA's share of biobased plastics volume is forecast at 0.9% in 2025 and 4.6% in 2035; bioplastics CAGR is forecast at 17.4%.

Feather upcycling

• Feathers are 90% protein, with 40 million tons discarded globally each year.

• Feather-derived hydrolysed protein powder for animal feed is intended to improve digestibility and nutritional value versus traditional methods, while replacing chemical- and energy-intensive hydrolysed feather meal.

• Local amino acid sourcing could support geopolitical resilience amid the EU's heavy dependence on imported amino acids.